新型冠状病毒

BioNTech/Pfizer vaccine is less potent against South African variant

Covid-19 jab still works but produces only a third of the antibodies it did for original virus, study finds

The BioNTech/Pfizer Covid-19 vaccine appears to be significantly less effective against the virus variant that emerged in South Africa, according to a study published on Wednesday. 

The vaccine still works against the strain known as 501Y.V2, but the shot produced only a third of the antibodies that it did for the original virus in a lab study using an engineered virus. 

The partners said there was “no clinical evidence” that people vaccinated with their Covid-19 shot lacked protection against the variant. It is hard to draw firm conclusions from lab experiments on how the vaccines will work on the variants in humans. 

您已阅读24%(624字),剩余76%(1951字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×